RCUS Price / Book | Arcus Biosciences, Inc.

Arcus Biosciences, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Arcus Biosciences, Inc. price/book ratio for the quarter ending 2026-06-30 was 8.45, a 435.08% increase year-over-year.
Arcus Biosciences, Inc. price/book ratio for the quarter ending 2026-03-31 was 5.18, a 230.90% increase year-over-year.
Arcus Biosciences, Inc. price/book ratio for the quarter ending 2025-12-31 was 4.73, a 67.17% increase year-over-year.
Arcus Biosciences, Inc. price/book ratio for the quarter ending 2025-09-30 was 3.34, a 34.92% increase year-over-year.
Arcus Biosciences, Inc. price/book ratio for fiscal 2026 was 8.45.
Arcus Biosciences, Inc. price/book ratio for fiscal 2025 was 4.73, a 67.17% increase from fiscal 2024.
Arcus Biosciences, Inc. price/book ratio for fiscal 2024 was 2.83, a 9.31% decline from fiscal 2023.
Arcus Biosciences, Inc. price/book ratio for fiscal 2023 was 3.12, a 36.03% increase from fiscal 2022.

Available history: 2018-03-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	8.45	$3.92B	$464M
2026-03-31	5.18	$2.71B	$524M
2025-12-31	4.73	$2.99B	$631M
2025-09-30	3.34	$1.46B	$436M
2025-06-30	1.58	$866.63M	$549M
2025-03-31	1.57	$831.32M	$531M
2024-12-31	2.83	$1.37B	$485M
2024-09-30	2.48	$1.4B	$565M
2024-06-30	2.19	$1.39B	$635M
2024-03-31	2.43	$1.72B	$707M
2023-12-31	3.12	$1.44B	$462M
2023-09-30	2.58	$1.34B	$520M
2023-06-30	2.67	$1.51B	$566M
2023-03-31	2.22	$1.33B	$600M
2022-12-31	2.29	$1.51B	$657M
2022-09-30	2.71	$1.89B	$699M
2022-06-30	2.45	$1.83B	$747M
2022-03-31	2.84	$2.26B	$797M
2021-12-31	3.4	$2.87B	$842M
2021-09-30	4.51	$2.45B	$542.61M
2021-06-30	3.24	$1.96B	$604.56M
2021-03-31	3	$1.99B	$664.79M
2020-12-31	3.37	$1.69B	$502M
2020-09-30	2.04	$1.11B	$544.42M
2020-06-30	3.4	$1.46B	$428.71M
2020-03-31	4.54	$638.24M	$140.64M
2019-12-31	2.83	$463.84M	$164M
2019-09-30	2.35	$417.17M	$177.23M
2019-06-30	1.85	$364.54M	$196.65M
2019-03-31	2.51	$556.24M	$221.57M
2018-12-31	2.04	$479.67M	$234.94M
2018-09-30	2.53	$619.68M	$245.12M
2018-06-30	2.14	$544.15M	$254.57M
2018-03-31	2.57	$686.37M	$266.59M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	8.45	$3.92B	$464M
2025-12-31	4.73	$2.99B	$631M
2024-12-31	2.83	$1.37B	$485M
2023-12-31	3.12	$1.44B	$462M
2022-12-31	2.29	$1.51B	$657M
2021-12-31	3.4	$2.87B	$842M
2020-12-31	3.37	$1.69B	$502M
2019-12-31	2.83	$463.84M	$164M
2018-12-31	2.04	$479.67M	$234.94M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Organon & Co. (OGN)	United States	$3.603B	17.03
PRECIGEN, INC. (PGEN)	United States	$2.757B	-12.94
NewAmsterdam Pharma Co N.V. (NAMS)		$2.719B	-15.37
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
MBX Biosciences, Inc. (MBX)	United States	$2.664B	-25.36